# Keros Therapeutics

Type: Company (KROS)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/keros-therapeutics
Canonical HTML page: https://getbiobrief.com/entity/keros-therapeutics

## Timeline

- **2026-03-04**: FY 2025 Earnings — Official reporting of full-year financial results and 2026 clinical guidance.
- **2026**: Cibotercept Data — Anticipated top-line data from the Phase 2 TROPOS trial in PAH patients.
- **2025-Q3**: KER-050 Expansion — Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS.
- **2025-Q1**: Capital Infusion — Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials.

## Recent coverage (1 stories)

### Keros Therapeutics Strengthens TGF-β Pipeline as 2025 Financials Signal Growth
2026-03-04 23:38:04 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026.
Full story: https://getbiobrief.com/story/keros-therapeutics-q4-2025-financial-results-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.